Emily Edson‐Heredia: Influence Statistics

Emily Edson‐Heredia

Emily Edson‐Heredia

Eli Lilly and Company, Indianapolis, Indiana, USA. | Eli Lilly and Company, Indianapolis, Indiana. | Eli Lilly and Company, Indianapolis, IN USA | Eli Lilly and Company, Lilly ...

Emily Edson‐Heredia: Expert Impact

Concepts for which Emily Edson‐Heredia has direct influence: Alopecia areata , Work productivity , Touch avoidance , Psoriatic arthritis , Biologic therapy , Palmoplantar psoriasis , Content validity .

Emily Edson‐Heredia: KOL impact

Concepts related to the work of other authors for which for which Emily Edson‐Heredia has influence: Psoriatic arthritis , Th17 cells , Patients psoriasis , Monoclonal antibodies , Work productivity , Atopic dermatitis , Biologic agents .

KOL Resume for Emily Edson‐Heredia


Eli Lilly and Company, Indianapolis, Indiana, USA.


Eli Lilly and Company, Indianapolis, Indiana.


Eli Lilly and Company, Indianapolis, IN, USA


Eli Lilly and Company, Indianapolis, IN, USA;, View further author information


Eli Lilly and Company, Indianapolis, Indiana


Lilly Corporate Center, Indianapolis, IN 46285, USA.


Eli Lilly & Co. Indianapolis IN USA


Eli Lilly and Co., Lilly, Corporate Center, Indianapolis, IN 46285, USA

HEOR Janssen Consultancy, Amsterdam, The Netherlands

Prominent publications by Emily Edson‐Heredia

KOL-Index: 16808 . BACKGROUND: Plaque psoriasis affects children and adults, but treatment options for paediatric psoriasis are limited. OBJECTIVES: To evaluate the efficacy and safety of ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, for moderate-to-severe paediatric psoriasis. METHODS: In a randomized, double-blind, placebo-controlled, phase III study ...
Known for Paediatric Patients | Ixekizumab Ixe | Severe Plaque | Efficacy Safety
KOL-Index: 14570 . IMPORTANCE: Therapies that reduce psoriasis symptoms may improve work productivity. OBJECTIVE: To assess the effect of ixekizumab therapy on work productivity, measured by the Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO). DESIGN, SETTING, AND PARTICIPANTS: Three multicenter, randomized double-blind phase 3 trials conducted during the following periods: December 2011 ...
Known for Work Productivity | Ixekizumab Treatment | Week Patients | Activity Impairment
KOL-Index: 13366 . BACKGROUND: Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evaluated the safety and efficacy of ixekizumab (LY2439821), a humanized anti-interleukin-17 monoclonal antibody, for psoriasis treatment. METHODS: In our phase 2, double-blind, ...
Known for Chronic Plaque Psoriasis | Ixekizumab Placebo | Pasi Score | Monoclonal Antibody
KOL-Index: 12008 . BACKGROUND: Biologic therapies have been used in patients with psoriatic arthritis (PsA) who have been inadequately treated with conventional disease-modifying anti-rheumatic drugs (DMARDs). OBJECTIVE: Examine treatment patterns and health care costs among patients with PsAs who initiated biologic therapy either as monotherapy or adjunctively with traditional DMARDs. METHODS: The ...
Known for Biologic Therapy | Treatment Patterns | Psoriatic Arthritis | Retrospective Cohort Study
KOL-Index: 11803 . BACKGROUND: Previous studies have demonstrated that patients with psoriasis have higher rates of comorbidities compared to the general population. Despite the clinical and economic burden of psoriatic disease, there have been few large-scale observational studies focused on this condition. OBJECTIVE: To assess rates of cardiovascular, autoimmune, infectious and other conditions in patients ...
Known for Psoriatic Arthritis | Patients Psoriasis | Incidence Rates | Cardiovascular Diseases
KOL-Index: 9746 . BACKGROUND: Itching is a profoundly distressing symptom for many patients with psoriasis, but it has not been rigorously studied using validated tools for this condition. OBJECTIVES: This study investigated the psychometric properties of the Itch Numeric Rating Scale (Itch NRS), a single-item patient-reported outcome (PRO) measuring the worst itching severity due to psoriasis in the past ...
Known for Plaque Psoriasis | Psychometric Properties | Itch Nrs | Baseline Week
KOL-Index: 9585 . BACKGROUND: Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance. OBJECTIVES: To investigate, in a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19-directed IL-23 antibody, vs. placebo in patients with moderate-to-severe plaque psoriasis. METHODS: Adult ...
Known for Plaque Psoriasis | Patients Mirikizumab | Efficacy Safety | Randomized Phase
KOL-Index: 9486 . BACKGROUND: Itch is a prevalent symptom of psoriasis that impacts quality of life. OBJECTIVE: We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3). METHODS: The itch numeric rating scale ...
Known for Skin Pain | Psoriasis Symptoms | Ixekizumab Patients | Itch Severity
KOL-Index: 9447 . BACKGROUND: The impact of palmoplantar psoriasis on health-related quality of life (QoL) is largely unknown. OBJECTIVE: We sought to compare clinical characteristics and patient-reported outcomes between patients with palmoplantar psoriasis and moderate to severe plaque psoriasis. METHODS: We conducted a cross-sectional study of patients with plaque psoriasis (N=1153) and palmoplantar ...
Known for Palmoplantar Psoriasis | Severe Plaque | Life Qol | Healthrelated Quality
KOL-Index: 8952 . BACKGROUND: In patients with moderate-to-severe psoriasis, health-related quality of life (HRQOL) has been shown to improve in parallel with improvement in disease severity. OBJECTIVES: To evaluate the role of pruritus (itch) in mediating the relationship between improvements in disease severity and HRQOL. METHODS: Data from a phase 2 clinical trial, in which 142 patients with ...
Known for Life Hrqol | Pruritus Psoriasis | Total Score | Quality Dlqi
KOL-Index: 8255 . BACKGROUND: Early identification of responsiveness to biologic treatments in psoriasis has significant clinical and economic implications. OBJECTIVES: To evaluate whether early clinical improvements in Psoriasis Area and Severity Index (PASI) scores could predict subsequent clinical responses in patients treated with ixekizumab, an anti-interleukin-17 monoclonal antibody. METHODS: This ...
Known for Pasi Week | Early Clinical | Plaque Psoriasis | Patients Ixekizumab
KOL-Index: 6358 . IntroductionPlaque psoriasis is a chronic skin disease where genital involvement is relatively common. Yet health care providers do not routinely evaluate psoriasis patients for genital involvement and patients do not readily initiate discussion of it.MethodsA qualitative study of 20 US patients with dermatologist-confirmed genital psoriasis (GenPs) and self-reported moderate-to-severe ...
Known for Genital Psoriasis | Patients Perspectives | Sexual Activity | Genps Symptoms
KOL-Index: 6133 . Plaque psoriasis (PP) and psoriatic arthritis (PsA) are autoinflammatory chronic conditions associated with skin involvement. Pruritus, or itching, is a prevalent and bothersome symptom in patients with PP and is associated with reduced health-related quality of life. The Worst Itch Numeric Rating Scale (WI-NRS) has been developed as a simple, single item with which to assess the ...
Known for Psoriatic Arthritis | Plaque Psoriasis | Patients Psa | Content Validity

Key People For Alopecia Areata

Top KOLs in the world
Jerry Shapiro
alopecia areata hair loss lichen planopilaris
Maria Kramarczuk Hordinsky
alopecia areata hair loss platelet rich plasma
Vera H Price
alopecia areata hair weight topical minoxidil
Madeleine A Duvic
mycosis fungoides cell lymphoma alopecia areata
Kevin John McElwee
alopecia areata hair follicle c3h hej mice
Ralf Paus
hair follicle human skin alopecia areata

Eli Lilly and Company, Indianapolis, Indiana, USA. | Eli Lilly and Company, Indianapolis, Indiana. | Eli Lilly and Company, Indianapolis, IN USA | Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA | Eli Lilly and Company, In